Indication for and Impact of Switching from Pirfenidone to Nintedanib in Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Hogben, C. [1 ]
Kouranos, V. [2 ]
Kokosi, M. [3 ]
Renzoni, E. A. [4 ]
Chua, F. [5 ]
Wells, A. U. [6 ]
Maher, T. M. [3 ]
Molyneaux, P. L. [5 ]
George, P. M. [7 ]
机构：
[1] Royal Brompton & Harefield NHS Fdn Trust, Interstitial Lung Dis Unit, London, England
[2] Royal Brompton Hosp, Interstitial Lung Dis, London, England
[3] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
[4] Imperial Coll, Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
[5] Royal Brompton & Harefield NHS Fdn Trust, London, England
[6] Royal Brompton Hosp, Resp, London, England
[7] Royal Brompton Hosp, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1635
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting
    Santos, Gabriela
    Fabiano, Andre
    Mota, Patricia Caetano
    Rodrigues, Ines
    Carvalho, Diogo
    Melo, Natalia
    Novais-Bastos, Helder
    Alexandre, Andre Terras
    Moura, Conceicao Souto
    Guimaraes, Susana
    Pereira, Jose Miguel
    Carvalho, Andre
    Morais, Antonio
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 83
  • [42] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, D.
    Jouneau, S.
    Bouzille, G.
    Polard, E.
    Osmont, M. N.
    Scailteux, L. M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 77 - 78
  • [43] Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
    C. C. Moor
    R. L. M. Mostard
    J. C. Grutters
    P. Bresser
    J. G. J. V. Aerts
    C. D. Dirksen
    M. L. Kimman
    M. S. Wijsenbeek
    Respiratory Research, 21
  • [44] Utilization of Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of US Claims Data
    Viscidi, Emma
    Wang, Nasha
    Hall, Susan
    Gallagher, Diana
    Eaton, Susan
    Dilley, Anne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 577 - 578
  • [45] Prescription Of Pirfenidone And Nintedanib For The Treatment Of Idiopathic Pulmonary Fibrosis (ipf): An Academic Center Experience
    Strock, S.
    Nouraie, S. M.
    Huttenhower, D.
    Chen, X.
    Lawson, K.
    Priore, M. Melissa
    Chiarchiaro, J.
    Veraldi, K. L.
    Lindell, K. O.
    Gibson, K. F.
    Kass, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [46] Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
    C. Rinciog
    A. Diamantopoulos
    A. Gentilini
    B. Bondue
    C. Dahlqvist
    A. Froidure
    W. A. Wuyts
    S. Soulard
    PharmacoEconomics - Open, 2020, 4 : 449 - 458
  • [47] Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?
    Gioele Castelli
    Elisabetta Cocconcelli
    Nicol Bernardinello
    Elisabetta Balestro
    Paolo Spagnolo
    Current Pulmonology Reports, 2023, 12 : 113 - 124
  • [48] Nintedanib for Idiopathic Pulmonary Fibrosis
    Tepede, Abisola
    Yogaratnam, Dinesh
    JOURNAL OF PHARMACY PRACTICE, 2019, 32 (02) : 199 - 206
  • [49] Pirfenidone in idiopathic pulmonary fibrosis
    Swigris, J.
    Fairclough, D.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (03) : 695 - 696
  • [50] PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS
    Maher, T. M.
    DRUGS OF TODAY, 2010, 46 (07) : 473 - 482
12345